Human Genome (hgsi): $825 Million.. - 500 Beiträge pro Seite

[zeder]

hi, wen´s interessiert:

gebe diese meldung (erst nachträglich auf ami-board gefunden) hier weiter, hilft vielleich, den kurs
der letzten Tage (zwischenzeitlicher rückfall von weit über 90 bis runter gegen 80 Dollar) etwas
besser nachzuvollziehen (bis börsenschluss zum glück wieder hochgemausert auf 88 $):

Human Genome Sciences Prices Offering of $825 Million of Common Stock

PR Newswire
Friday October 27 8:15am

ROCKVILLE, Md., Oct. 27 /PRNewswire/ -- Human Genome Sciences, Inc. (Nasdaq: HGSI) today
announced that it has priced a public offering by the Company of 11,000,000 shares of its
Common Stock at a price of $75.00 per share. Gross proceeds totaled approximately $825 million.
The offering was led by Credit Suisse First Boston and co-managed by Goldman, Sachs & Co.,
Lehman Brothers, CIBC World Markets, J.P. Morgan & Co. and Dain Rauscher Wessels.

The underwriters have an option to purchase an additional 1,650,000 shares to cover
over-allotments, if any. Copies of a prospectus with respect to this offering may be obtained from
Credit Suisse First Boston, c/o Prospectus Department, 11 Madison Avenue, New York, New York
10010, tel. [phone], or by faxing requests to 212-325-8057.

HGS expects to use the net proceeds from this offering to continue the initiation and expansion of
laboratory and human studies to evaluate additional protein-, gene- and antibody-based drugs, to
accelerate ongoing research and development efforts and explore new opportunities in a variety of
fields, to pursue patent coverage for HGS` genes and potential products, to operate and expand
process development and manufacturing facilities, to acquire complementary products or
companies and develop partnerships in other areas of drug development that further HGS` strategic
goal of becoming a fully-integrated global pharmaceutical company, and for general corporate
purposes.

Human Genome Sciences is a company with the mission to treat and cure disease by bringing new
gene-based drugs to patients.

HGS and Human Genome Sciences are registered trademarks of Human Genome Sciences, Inc.

This announcement contains forward-looking statements within the meaning of Section 27A of the
Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. The forward-looking statements are based on Human Genome Sciences` current intent,
belief and expectations. These statements are not guarantees of future performance and are
subject to certain risks and uncertainties that are difficult to predict. Actual results may differ
materially from these forward-looking statements because of the company`s unproven business
model, dependence on new technologies, uncertainty as to clinical trial results, ability to develop
and commercialize products, dependence on collaborators for services and revenue, substantial
indebtedness, intense competition, uncertainty of patent and intellectual property protection,
dependence on key management, uncertainty of regulation of products, dependence on key
suppliers and other risks that may be described in the company`s filings with the Securities and
Exchange Commission. Existing and prospective investors are cautioned not to place undue
reliance on these forward-looking statements, which speak only as of today`s date. Human Genome
Sciences undertakes no obligation to update or revise the information contained in this
announcement whether as a result of new information, future events or circumstances or otherwise.

Source:
Human Genome Sciences, Inc.
Contact:
Kate de Santis, Director, Corporate Communications and Investor Relations, Human
Genome Sciences, 301-309-8504



Source: PR Newswire

soweit die facts.

sich vergrübelt fragend, wo wohl der kurs jetzt stünde, hätte man den
preis ein bisserl höher angesetzt,
wünsch ich euch allen eine schönes wochenende, einen guten novemberstart
und eine fröhliche kleine herbststernfahrt...

gruß
zeder

[Asia-T]

hier mal ne chartanalyse



sieht doch ganz gut aus, oder?
Sowohl der Langfristige als auch der mittelfristige Abwärtstrend konnten bestätigt durchbrochen werden. Durch den Ausbruch aus einer Dreicksformation nach den durch die beiden Doppeltops entstandenen Verkaufssignale wird nun ein kursfristiges Kursziel von 80 USD generiert.

Außerdem besteht wie ich finde ein sehr gutes Changen/Risiko Verhältnis wenn der Wert mit einem SL bei 60 USD abgesichert wird.

gruß
asia